Predictors of Treatment Response to Biological Medications in Patients with Rheumatoid Arthritis

Abstract

Background: Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease characterized primarily by persistent synovitis, progressive joint destruction, functional impairment, and reduced quality of life. Biological disease-modifying antirheumatic drugs (bDMARDs) have substantially improved the management of moderate-to-severe RA, particularly in patients with inadequate responses to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Nevertheless, considerable variability exists in clinical response, treatment persistence, and adverse-event profiles among individual patients.

Objective: This review evaluates clinical, demographic, serological, genetic, pharmacological, and lifestyle-related factors associated with treatment response to biological medications in patients with RA. It also discusses the potential role of biomarkers and precision medicine in optimizing biological therapy selection.

Methods: A narrative review approach was used to synthesize evidence regarding predictors of response to major biological therapies used for RA, including tumor necrosis factor inhibitors (TNFi), interleukin-6 (IL-6) pathway inhibitors, B-cell-directed therapy, and T-cell costimulation modulators. Particular attention was given to factors that may be applicable to routine clinical practice.

Results: Treatment response to biological therapy appears to be influenced by multiple interacting variables rather than a single predictive marker. Important factors include baseline disease activity, disease duration, previous treatment exposure, rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) status, smoking, obesity, treatment adherence, concomitant methotrexate use, and immunogenicity. Certain predictors may be treatment-specific. For example, seropositivity has been associated with improved responses to some non-TNF biological agents, whereas obesity may negatively influence the effectiveness of some TNF inhibitors.

Conclusion: Identification of predictors of biological treatment response may improve individualized treatment selection in RA. However, no single biomarker currently provides sufficient accuracy to independently determine the optimal biological agent. Future strategies combining clinical characteristics, molecular biomarkers, pharmacogenomics, therapeutic drug monitoring, and machine-learning models may facilitate precision medicine in RA.